High-Dose Lanreotide Autogel in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumours
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
Eur. J. Cancer 2021 Nov 01;157(xx)403-414, M Pavel, JB Ćwikła, C Lombard-Bohas, I Borbath, T Shah, UF Pape, J Capdevila, F Panzuto, XM Truong Thanh, A Houchard, P RuszniewskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.